TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. More Details
Excellent balance sheet and overvalued.
Share Price & News
How has TMC Life Sciences Berhad's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TMCLIFE is not significantly more volatile than the rest of MY stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: TMCLIFE's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: TMCLIFE exceeded the MY Healthcare industry which returned 9.4% over the past year.
Return vs Market: TMCLIFE exceeded the MY Market which returned -0.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is TMC Life Sciences Berhad's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StTMC Life Sciences Berhad (KLSE:TMCLIFE) Shareholders Will Want The ROCE Trajectory To Continue
5 months ago | Simply Wall StTMC Life Sciences Berhad's (KLSE:TMCLIFE) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Is TMC Life Sciences Berhad undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TMCLIFE (MYR0.6) is trading above our estimate of fair value (MYR0.03)
Significantly Below Fair Value: TMCLIFE is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TMCLIFE is poor value based on its PE Ratio (65.6x) compared to the MY Healthcare industry average (56.8x).
PE vs Market: TMCLIFE is poor value based on its PE Ratio (65.6x) compared to the MY market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TMCLIFE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TMCLIFE is good value based on its PB Ratio (1.4x) compared to the MY Healthcare industry average (3x).
How is TMC Life Sciences Berhad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as TMC Life Sciences Berhad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has TMC Life Sciences Berhad performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: TMCLIFE has a high level of non-cash earnings.
Growing Profit Margin: TMCLIFE's current net profit margins (8.7%) are lower than last year (15.2%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TMCLIFE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: TMCLIFE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TMCLIFE had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Healthcare industry average (-7.8%).
Return on Equity
High ROE: TMCLIFE's Return on Equity (2.1%) is considered low.
How is TMC Life Sciences Berhad's financial position?
Financial Position Analysis
Short Term Liabilities: TMCLIFE's short term assets (MYR185.9M) exceed its short term liabilities (MYR69.9M).
Long Term Liabilities: TMCLIFE's short term assets (MYR185.9M) exceed its long term liabilities (MYR108.4M).
Debt to Equity History and Analysis
Debt Level: TMCLIFE's debt to equity ratio (10.6%) is considered satisfactory.
Reducing Debt: TMCLIFE's debt to equity ratio has increased from 0.5% to 10.6% over the past 5 years.
Debt Coverage: TMCLIFE's debt is well covered by operating cash flow (21.5%).
Interest Coverage: TMCLIFE earns more interest than it pays, so coverage of interest payments is not a concern.
What is TMC Life Sciences Berhad current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TMCLIFE's dividend (0.28%) isn’t notable compared to the bottom 25% of dividend payers in the MY market (1.49%).
High Dividend: TMCLIFE's dividend (0.28%) is low compared to the top 25% of dividend payers in the MY market (4.17%).
Stability and Growth of Payments
Stable Dividend: TMCLIFE is not paying a notable dividend for the MY market, therefore no need to check if payments are stable.
Growing Dividend: TMCLIFE is not paying a notable dividend for the MY market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TMCLIFE is not paying a notable dividend for the MY market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TMCLIFE's dividend in 3 years as they are not forecast to pay a notable one for the MY market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wan Binti Wan Mohd Abdullah Yaakob (37 yo)
Ms. Wan Nadiah Binti Wan Mohd Abdullah Yaakob has been the Group Chief Executive Officer of TMC Life Sciences Berhad since February 01, 2019. Ms. Binti Wan Mohd Abdullah Yaakob has been Executive Director ...
CEO Compensation Analysis
Compensation vs Market: Wan's total compensation ($USD257.32K) is above average for companies of similar size in the MY market ($USD192.52K).
Compensation vs Earnings: Insufficient data to compare Wan's compensation with company performance.
Experienced Management: TMCLIFE's management team is considered experienced (2.2 years average tenure).
Experienced Board: TMCLIFE's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
TMC Life Sciences Berhad's company bio, employee growth, exchange listings and data sources
- Name: TMC Life Sciences Berhad
- Ticker: TMCLIFE
- Exchange: KLSE
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: RM1.045b
- Shares outstanding: 1.74b
- Website: https://www.tmclife.com
- TMC Life Sciences Berhad
- C-13-09 Sunway Nexis
- No. 1, Jalan PJU 5/1
- Petaling Jaya
TMC Life Sciences Berhad, an investment holding company, provides healthcare services in Malaysia. It operates Thomson Hospital Kota Damansara (THKD), a 205-bedded medical center located in Selangor. The c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/30 17:22|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.